Santhera Pharmaceuticals Holding AG (SANN.SW)
CHF 9.86
(2.49%)
CHF 9.86
(2.49%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 79.17 Million CHF | 226.0% |
| 2022 | -46.77 Million CHF | 1.7% |
| 2021 | -34.57 Million CHF | 19.83% |
| 2020 | -53.42 Million CHF | -656.45% |
| 2019 | -7.54 Million CHF | 85.21% |
| 2018 | -45.62 Million CHF | -3.48% |
| 2017 | -44.05 Million CHF | -55.74% |
| 2016 | -29.92 Million CHF | -29.86% |
| 2015 | 4.05 Million CHF | -209.22% |
| 2014 | -7.86 Million CHF | -44.91% |
| 2013 | -5.68 Million CHF | 53.66% |
| 2012 | -11.09 Million CHF | 51.1% |
| 2011 | -22.48 Million CHF | -1007.32% |
| 2010 | -2.49 Million CHF | -106.66% |
| 2009 | -20.95 Million CHF | 178.72% |
| 2008 | -39.07 Million CHF | -30.13% |
| 2007 | -27.61 Million CHF | -8.72% |
| 2006 | -26.57 Million CHF | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -7.48 Million CHF | 0.0% |
| 2024 Q1 | -7.48 Million CHF | -108.07% |
| 2023 Q2 | -18.52 Million CHF | -100.43% |
| 2023 Q3 | 36.32 Million CHF | 296.12% |
| 2023 Q4 | 72.06 Million CHF | 98.4% |
| 2023 Q1 | -9.24 Million CHF | 50.03% |
| 2023 FY | - CHF | 226.0% |
| 2022 Q4 | -18.49 Million CHF | -76.61% |
| 2022 Q3 | -10.46 Million CHF | 55.88% |
| 2022 Q2 | -23.72 Million CHF | -119.51% |
| 2022 Q1 | -10.81 Million CHF | 69.85% |
| 2022 FY | - CHF | 1.7% |
| 2021 FY | - CHF | 19.83% |
| 2021 Q4 | -35.85 Million CHF | -99.17% |
| 2021 Q1 | -8.79 Million CHF | 61.41% |
| 2021 Q2 | -17.55 Million CHF | -99.65% |
| 2021 Q3 | -18 Million CHF | -2.57% |
| 2020 Q1 | -11.76 Million CHF | -183.01% |
| 2020 Q2 | -23.64 Million CHF | -100.93% |
| 2020 Q3 | -13.03 Million CHF | 44.86% |
| 2020 FY | - CHF | -656.45% |
| 2020 Q4 | -22.78 Million CHF | -74.72% |
| 2019 Q3 | 6.6 Million CHF | 133.0% |
| 2019 FY | - CHF | 85.21% |
| 2019 Q2 | -20 Million CHF | -99.5% |
| 2019 Q1 | -10.02 Million CHF | 29.02% |
| 2019 Q4 | 14.17 Million CHF | 114.77% |
| 2018 Q4 | -14.12 Million CHF | -47.13% |
| 2018 FY | - CHF | -3.48% |
| 2018 Q3 | -9.6 Million CHF | 21.33% |
| 2018 Q2 | -12.2 Million CHF | 0.0% |
| 2018 Q1 | -12.2 Million CHF | 23.44% |
| 2017 Q2 | -9.84 Million CHF | 0.0% |
| 2017 FY | - CHF | -55.74% |
| 2017 Q4 | -15.94 Million CHF | -72.19% |
| 2017 Q3 | -9.25 Million CHF | 6.02% |
| 2017 Q1 | -9.84 Million CHF | -37.45% |
| 2016 FY | - CHF | -29.86% |
| 2016 Q4 | -7.16 Million CHF | 0.0% |
| 2016 Q3 | -7.16 Million CHF | 8.06% |
| 2016 Q2 | -7.79 Million CHF | 0.0% |
| 2016 Q1 | -7.79 Million CHF | 0.78% |
| 2015 Q4 | -7.85 Million CHF | 0.0% |
| 2015 Q2 | -3.08 Million CHF | 0.0% |
| 2015 FY | - CHF | -209.22% |
| 2015 Q1 | -3.08 Million CHF | -28.0% |
| 2015 Q3 | -7.85 Million CHF | -154.37% |
| 2014 Q1 | -1.52 Million CHF | -56.83% |
| 2014 FY | - CHF | -44.91% |
| 2014 Q4 | -2.41 Million CHF | 0.0% |
| 2014 Q3 | -2.41 Million CHF | -58.51% |
| 2014 Q2 | -1.52 Million CHF | 0.0% |
| 2013 Q2 | -2.11 Million CHF | 0.0% |
| 2013 Q1 | -2.11 Million CHF | 25.21% |
| 2013 FY | - CHF | 53.66% |
| 2013 Q4 | -970.5 Thousand CHF | 0.0% |
| 2013 Q3 | -970.5 Thousand CHF | 54.12% |
| 2012 Q3 | -2.82 Million CHF | 0.0% |
| 2012 FY | - CHF | 51.1% |
| 2012 Q4 | -2.82 Million CHF | 0.0% |
| 2011 FY | - CHF | -1007.32% |
| 2010 FY | - CHF | -106.66% |
| 2009 FY | - CHF | 178.72% |
| 2008 FY | - CHF | -30.13% |
| 2007 FY | - CHF | -8.72% |
| 2006 FY | - CHF | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Addex Therapeutics Ltd | -10.22 Million CHF | 874.04% |
| BB Biotech AG | -201.25 Million CHF | 139.34% |
| Basilea Pharmaceutica AG | 29.49 Million CHF | -168.432% |
| Evolva Holding SA | -98.35 Million CHF | 180.496% |
| Idorsia Ltd | -254.55 Million CHF | 131.103% |
| Kuros Biosciences AG | -10.4 Million CHF | 860.63% |
| Molecular Partners AG | -59.51 Million CHF | 233.032% |
| Relief Therapeutics Holding AG | -108.2 Million CHF | 173.172% |